About Voyager Therapeutics, Inc.
https://www.voyagertherapeutics.comVoyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease.
CEO
Alfred W. Sandrock Jr.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 68
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
Wedbush
Outperform
Cantor Fitzgerald
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.61M
Value:$23.16M
BLACKROCK INC.
Shares:5.31M
Value:$21.94M
ARMISTICE CAPITAL, LLC
Shares:4.8M
Value:$19.82M
Summary
Showing Top 3 of 142
About Voyager Therapeutics, Inc.
https://www.voyagertherapeutics.comVoyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $13.37M ▲ | $43.96M ▲ | $-27.89M ▲ | -208.69% ▲ | $-0.47 ▲ | $-26.88M ▲ |
| Q2-2025 | $5.2M ▼ | $41.83M ▲ | $-33.38M ▼ | -641.96% ▼ | $-0.57 ▼ | $-35.56M ▼ |
| Q1-2025 | $6.47M ▲ | $41.17M ▼ | $-31.02M ▲ | -479.24% ▲ | $-0.53 ▲ | $-33.68M ▲ |
| Q4-2024 | $6.28M ▼ | $44.58M ▲ | $-34.49M ▼ | -549.33% ▼ | $-0.59 ▼ | $-37.29M ▼ |
| Q3-2024 | $24.63M | $38.41M | $-9.04M | -36.72% | $-0.16 | $-12.65M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $208.93M ▼ | $288.31M ▼ | $68.49M ▼ | $219.82M ▼ |
| Q2-2025 | $215.59M ▼ | $322.1M ▼ | $78.16M ▼ | $243.94M ▼ |
| Q1-2025 | $236.02M ▼ | $353.24M ▼ | $80.54M ▼ | $272.7M ▼ |
| Q4-2024 | $266.68M ▼ | $393.05M ▼ | $93.29M ▼ | $299.76M ▼ |
| Q3-2024 | $345.36M | $426.04M | $95.73M | $330.31M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-27.89M ▲ | $-31.05M ▲ | $34.89M ▲ | $85K ▼ | $1.19M ▲ | $-31.25M ▲ |
| Q2-2025 | $-33.38M ▼ | $-33.26M ▲ | $1.93M ▼ | $513K ▲ | $-30.82M ▼ | $-34.37M ▲ |
| Q1-2025 | $-31.02M ▲ | $-37.9M ▼ | $41.2M ▲ | $82K ▼ | $3.39M ▲ | $-38.55M ▼ |
| Q4-2024 | $-34.49M ▼ | $-14.53M ▲ | $-27.2M ▼ | $574K ▲ | $-41.16M ▼ | $-14.68M ▲ |
| Q3-2024 | $-9.04M | $-27.97M | $64.35M | $14K | $36.4M | $-28.23M |
CEO
Alfred W. Sandrock Jr.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 68
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
Wedbush
Outperform
Cantor Fitzgerald
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.61M
Value:$23.16M
BLACKROCK INC.
Shares:5.31M
Value:$21.94M
ARMISTICE CAPITAL, LLC
Shares:4.8M
Value:$19.82M
Summary
Showing Top 3 of 142